> top > docs > PubMed:26586780 > annotations

PubMed:26586780 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-78 Sentence denotes Causes of late mortality with dual antiplatelet therapy after coronary stents.
T2 79-84 Sentence denotes AIMS:
T3 85-271 Sentence denotes In the dual antiplatelet therapy (DAPT) study, continued thienopyridine beyond 12 months after drug-eluting stent placement was associated with increased mortality compared with placebo.
T4 272-415 Sentence denotes We sought to evaluate factors related to mortality in randomized patients receiving either drug-eluting or bare metal stents in the DAPT study.
T5 416-436 Sentence denotes METHODS AND RESULTS:
T6 437-707 Sentence denotes Patients were enrolled after coronary stenting, given thienopyridine and aspirin for 12 months, randomly assigned to continued thienopyridine or placebo for an additional 18 months (while taking aspirin), and subsequently treated with aspirin alone for another 3 months.
T7 708-770 Sentence denotes A blinded independent adjudication committee evaluated deaths.
T8 771-1059 Sentence denotes Among 11 648 randomized patients, rates of all-cause mortality rates were 1.9 vs. 1.5% (continued thienopyridine vs. placebo, P = 0.07), cardiovascular mortality, 1.0 vs. 1.0% (P = 0.97), and non-cardiovascular mortality, 0.9 vs. 0.5% (P = 0.01) over the randomized period (Months 12-30).
T9 1060-1199 Sentence denotes Rates of fatal bleeding were 0.2 vs. 0.1% (P = 0.81), and deaths related to any prior bleeding were 0.3 vs. 0.2% (P = 0.36), Months 12-33).
T10 1200-1257 Sentence denotes Cancer incidence did not differ (2.0 vs. 1.6%, P = 0.12).
T11 1258-1374 Sentence denotes Cancer-related deaths occurred in 0.6 vs. 0.3% (P = 0.02) and were rarely related to bleeding (0.1 vs. 0, P = 0.25).
T12 1375-1494 Sentence denotes After excluding those occurring in patients with cancer diagnosed before enrolment, rates were 0.4 vs. 0.3% (P = 0.16).
T13 1495-1506 Sentence denotes CONCLUSION:
T14 1507-1604 Sentence denotes Bleeding accounted for a minority of deaths among patients treated with continued thienopyridine.
T15 1605-1732 Sentence denotes Cancer-related death in association with thienopyridine therapy was mainly not related to bleeding and may be a chance finding.
T16 1733-1828 Sentence denotes Caution is warranted when considering extended thienopyridine in patients with advanced cancer.
T17 1829-1892 Sentence denotes TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00977938.
T1 0-78 Sentence denotes Causes of late mortality with dual antiplatelet therapy after coronary stents.
T2 79-84 Sentence denotes AIMS:
T3 85-271 Sentence denotes In the dual antiplatelet therapy (DAPT) study, continued thienopyridine beyond 12 months after drug-eluting stent placement was associated with increased mortality compared with placebo.
T4 272-415 Sentence denotes We sought to evaluate factors related to mortality in randomized patients receiving either drug-eluting or bare metal stents in the DAPT study.
T5 416-436 Sentence denotes METHODS AND RESULTS:
T6 437-707 Sentence denotes Patients were enrolled after coronary stenting, given thienopyridine and aspirin for 12 months, randomly assigned to continued thienopyridine or placebo for an additional 18 months (while taking aspirin), and subsequently treated with aspirin alone for another 3 months.
T7 708-770 Sentence denotes A blinded independent adjudication committee evaluated deaths.
T8 771-1059 Sentence denotes Among 11 648 randomized patients, rates of all-cause mortality rates were 1.9 vs. 1.5% (continued thienopyridine vs. placebo, P = 0.07), cardiovascular mortality, 1.0 vs. 1.0% (P = 0.97), and non-cardiovascular mortality, 0.9 vs. 0.5% (P = 0.01) over the randomized period (Months 12-30).
T9 1060-1199 Sentence denotes Rates of fatal bleeding were 0.2 vs. 0.1% (P = 0.81), and deaths related to any prior bleeding were 0.3 vs. 0.2% (P = 0.36), Months 12-33).
T10 1200-1257 Sentence denotes Cancer incidence did not differ (2.0 vs. 1.6%, P = 0.12).
T11 1258-1374 Sentence denotes Cancer-related deaths occurred in 0.6 vs. 0.3% (P = 0.02) and were rarely related to bleeding (0.1 vs. 0, P = 0.25).
T12 1375-1494 Sentence denotes After excluding those occurring in patients with cancer diagnosed before enrolment, rates were 0.4 vs. 0.3% (P = 0.16).
T13 1495-1506 Sentence denotes CONCLUSION:
T14 1507-1604 Sentence denotes Bleeding accounted for a minority of deaths among patients treated with continued thienopyridine.
T15 1605-1732 Sentence denotes Cancer-related death in association with thienopyridine therapy was mainly not related to bleeding and may be a chance finding.
T16 1733-1828 Sentence denotes Caution is warranted when considering extended thienopyridine in patients with advanced cancer.
T17 1829-1892 Sentence denotes TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00977938.